JP2024540922A5 - - Google Patents
Info
- Publication number
- JP2024540922A5 JP2024540922A5 JP2024523525A JP2024523525A JP2024540922A5 JP 2024540922 A5 JP2024540922 A5 JP 2024540922A5 JP 2024523525 A JP2024523525 A JP 2024523525A JP 2024523525 A JP2024523525 A JP 2024523525A JP 2024540922 A5 JP2024540922 A5 JP 2024540922A5
- Authority
- JP
- Japan
- Prior art keywords
- crystal according
- approximately
- solution
- powder
- ray diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163257073P | 2021-10-18 | 2021-10-18 | |
| US63/257,073 | 2021-10-18 | ||
| PCT/EP2022/078989 WO2023066941A1 (en) | 2021-10-18 | 2022-10-18 | Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540922A JP2024540922A (ja) | 2024-11-06 |
| JP2024540922A5 true JP2024540922A5 (enExample) | 2025-10-27 |
Family
ID=84359608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024523525A Pending JP2024540922A (ja) | 2021-10-18 | 2022-10-18 | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素のエタノール溶媒和物の結晶形 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250066382A1 (enExample) |
| EP (1) | EP4419530A1 (enExample) |
| JP (1) | JP2024540922A (enExample) |
| CN (1) | CN118451082A (enExample) |
| WO (1) | WO2023066941A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3518933B2 (en) | 2016-09-30 | 2025-02-26 | Sumitomo Pharma Switzerland GmbH | Methods of treating uterine fibroids and endometriosis |
| JP2022551316A (ja) | 2019-10-10 | 2022-12-08 | ミオバント サイエンシズ ゲーエムベーハー | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形 |
| BR112022023937A2 (pt) | 2020-05-29 | 2022-12-27 | Myovant Sciences Gmbh | Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1591446B1 (en) | 2003-01-29 | 2013-03-06 | Takeda Pharmaceutical Company Limited | Thienopyrimidine compounds and use thereof |
| PL2900675T3 (pl) | 2012-09-28 | 2019-08-30 | Takeda Pharmaceutical Company Limited | Sposób wytwarzania pochodnej tienopirymidyny |
| CA2978223A1 (en) | 2015-02-26 | 2016-09-01 | Takeda Pharmaceutical Company Limited | Formulations of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethyl amino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| EP3518933B2 (en) | 2016-09-30 | 2025-02-26 | Sumitomo Pharma Switzerland GmbH | Methods of treating uterine fibroids and endometriosis |
| CN110248661A (zh) | 2016-09-30 | 2019-09-17 | 梦欧文科学有限责任公司 | 前列腺癌的治疗 |
| WO2019178304A1 (en) * | 2018-03-14 | 2019-09-19 | Teva Pharmaceuticals International Gmbh | Solid state forms of relugolix |
| JP2022551316A (ja) | 2019-10-10 | 2022-12-08 | ミオバント サイエンシズ ゲーエムベーハー | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形 |
| EP4041738A1 (en) | 2019-10-10 | 2022-08-17 | Myovant Sciences GmbH | Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
-
2022
- 2022-10-18 WO PCT/EP2022/078989 patent/WO2023066941A1/en not_active Ceased
- 2022-10-18 EP EP22805826.9A patent/EP4419530A1/en active Pending
- 2022-10-18 JP JP2024523525A patent/JP2024540922A/ja active Pending
- 2022-10-18 CN CN202280069988.XA patent/CN118451082A/zh active Pending
-
2024
- 2024-04-16 US US18/636,642 patent/US20250066382A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024540922A5 (enExample) | ||
| JP2022551525A5 (enExample) | ||
| JP2022551316A5 (enExample) | ||
| KR100207360B1 (ko) | 이미다조[1,5,-a]퀸옥살린 | |
| JP4193949B2 (ja) | Ｉ型グリシン輸送阻害剤としての二環式［３．１．０］ヘテロアリールアミド | |
| ES2604542T3 (es) | Arilamidas con sustitución tetrazol | |
| US5629331A (en) | Process for the preparation of a tetrazole derivative in two crystalline forms and novel the crystalline forms thereof | |
| JP4740115B2 (ja) | 置換ピラゾール | |
| JP6240164B2 (ja) | ピロール誘導体の結晶及びその製造方法 | |
| US20090149505A1 (en) | Metabotropic Glutamate Receptor-Potentiating Isoindolones | |
| JP2008514642A5 (enExample) | ||
| TW200838511A (en) | Novel pharmaceutical compounds | |
| TW200521115A (en) | Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors | |
| EP2118067A1 (en) | Nicotinic acetylcholine receptor modulators | |
| JPH06508370A (ja) | アンジオテンシン２拮抗活性を有する４−（１ｈ−ピロール−１−イル）イミダゾール | |
| JPH054391B2 (enExample) | ||
| JP2022533340A5 (enExample) | ||
| JPH04257570A (ja) | ピペラジン誘導体 | |
| JP2024514090A5 (enExample) | ||
| CA2521202A1 (en) | 1,3,4-substituted pyrazoles for use as 5-ht receptor antagonists in the treatment of psychoses and neurological disorders | |
| WO2024193530A1 (zh) | 萘胺类线粒体自噬诱导剂的固体形式、其制备方法、药物组合物和用途 | |
| AU2004228119B2 (en) | Pyrazole compounds | |
| WO2009095394A1 (en) | Diazepanes as histamine h3 receptor antagonists | |
| JP4385414B2 (ja) | アミド若しくはアミン誘導体 | |
| JP2022535870A (ja) | Ｃｄｋ９阻害剤の結晶多形体及びその製造方法と用途 |